Impact of Cytogenetic Risk on Outcomes of Non-T Cell Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia.

[1]  Yu-Hong Chen,et al.  Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation , 2021, Cellular & Molecular Immunology.

[2]  N. Kröger,et al.  Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia , 2020, Bone Marrow Transplantation.

[3]  J. Esteve,et al.  Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years , 2020, Clinical Cancer Research.

[4]  J. Esteve,et al.  The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT) , 2020, American journal of hematology.

[5]  F. Thol,et al.  Treatment of Relapsed Acute Myeloid Leukemia , 2020, Current Treatment Options in Oncology.

[6]  M. Labopin,et al.  Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT , 2020, Journal of Hematology & Oncology.

[7]  H. Brenner,et al.  Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century , 2020, Blood Cancer Journal.

[8]  M. Abdul-Hay,et al.  Haploidentical Hematopoietic Stem Cell Transplantation Followed by ‘Post-Cyclophosphamide’: The Future of Allogeneic Stem Cell Transplant , 2020, Clinical hematology international.

[9]  C. Buske,et al.  Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  R. Champlin.  Is unrelated donor or haploidentical hematopoietic transplantation preferred for patients with acute myeloid leukemia in remission? , 2020, Haematologica.

[11]  Cosmin A. Tegla,et al.  Current Status and Future Directions in Graft-Versus-Host Disease Prevention Following Allogeneic Blood and Marrow Transplantation in Adults , 2020, Clinical hematology international.

[12]  A. Nagler,et al.  Summary of Scientific and Statistical Methods, Study Endpoints and Definitions for Observational and Registry-Based Studies in Hematopoietic Cell Transplantation , 2019, Clinical hematology international.

[13]  J. Esteve,et al.  The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA‐matched allogeneic stem cell transplantation , 2019, American journal of hematology.

[14]  S. Montoto,et al.  Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. , 2019, The Lancet. Haematology.

[15]  J. Esteve,et al.  Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT , 2019, Haematologica.

[16]  K. Culos,et al.  Salvage Therapy after Allogeneic Hematopoietic Cell Transplantation: Targeted and Low-Intensity Treatment Options in Myelodysplastic Syndrome and Acute Myeloid Leukemia , 2019, Clinical hematology international.

[17]  R. Fanin,et al.  Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT , 2019, Bone Marrow Transplantation.

[18]  J. Esteve,et al.  Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia , 2019, Leukemia.

[19]  H. Einsele,et al.  Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT , 2018, Haematologica.

[20]  J. Esteve,et al.  Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center , 2018, Cancer.

[21]  J. Esteve,et al.  AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation , 2018, Bone Marrow Transplantation.

[22]  M. Labopin,et al.  Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide , 2018, Cancer.

[23]  S. Montoto,et al.  Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report , 2017, Bone Marrow Transplantation.

[24]  M. Labopin,et al.  Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant , 2017, Haematologica.

[25]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[26]  K. Döhner,et al.  Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia , 2017, Leukemia.

[27]  J. Esteve,et al.  Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) , 2015, Journal of Hematology & Oncology.

[28]  K. Döhner,et al.  Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure , 2017, Leukemia.

[29]  P. Vyas,et al.  An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation , 2016, Haematologica.

[30]  M. Labopin,et al.  Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP–EBMT analysis on patients with AML in remission , 2016, Bone Marrow Transplantation.

[31]  R. Bouabdallah,et al.  The patient’s CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide , 2016, Bone Marrow Transplantation.

[32]  M. Labopin,et al.  Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. , 2015, The Lancet. Haematology.

[33]  F. Appelbaum,et al.  Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia , 2015, Haematologica.

[34]  Daniel J Weisdorf,et al.  Acute Myeloid Leukemia. , 2015, The New England journal of medicine.

[35]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[36]  E. Vellenga,et al.  Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Alan M. Miller,et al.  Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[38]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[39]  B. Sandmaier,et al.  Defining the intensity of conditioning regimens: working definitions. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[40]  M. Slovak,et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study , 2000 .

[41]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.